

Postponed or immediate drainage of infected necrotizing pancreatitis (POINTER trial)

Submission date 02/07/2015	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 06/08/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 02/09/2025	Condition category Digestive System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Acute pancreatitis is a common disease where the pancreas becomes inflamed over a short period of time. During an acute pancreatitis attack, tissue within the pancreas may die (necrotize) and later become infected. Infected necrosis is associated with a mortality (death rate) of 20% and many other complications. Current guidelines recommend a so-called 'step-up approach' in these patients, starting with first catheter drainage. If necessary, patients will have an additional operation to remove their infected necrosis (necrosectomy). All these interventions are preferably delayed until the necrotic collections have reached the stage of walled-off necrosis. This process usually takes 4 weeks. During this waiting period antibiotic treatment is used. There is evidence that necrosectomy (second step) should be postponed until walled-off necrosis. However, evidence regarding the best timing of catheter drainage (first step) is lacking. This study aims to compare immediate and postponed catheter drainage in patients with infected necrotizing pancreatitis with regard to clinical outcomes and medical costs.

Who can participate?

Adult patients with (suspected) infected necrotizing pancreatitis.

What does the study involve?

Participants will be randomly allocated to either the intervention or the control group. Participants will undergo the same treatment as non-participating patients. The only difference is that participants in the intervention group will undergo catheter drainage earlier in the disease course. Participants will attend follow-up visits 3 and 6 months later to undergo routine tests (e.g., pancreatic function tests and imaging).

What are the possible benefits and risks of participating?

There is a rationale in postponing catheter drainage in patients with infected necrotizing pancreatitis. First, antibiotic treatment alone may suffice as treatment. Second, diagnosing infected necrotizing pancreatitis is often easier in a later stage of the disease. Third, catheter drainage may be easier once the stage of walled-off necrosis has been reached. On the other hand there is not always a technical reason to wait several weeks until full encapsulation of the collections and catheter drainage can be performed successfully in the first weeks after onset of

disease. For similar abdominal conditions catheter drainage is also safely performed early in 'non-walled-off' collections. If there is no technical reason for postponing catheter drainage, patients with infected necrotizing pancreatitis may benefit from earlier catheter drainage by reduced complications and length of hospital stay.

Where is the study run from?

The study is initiated by the Dutch Pancreatitis Study Group (DPSG) and 24 Dutch hospitals will participate.

When is the study starting and how long is it expected to run for?

The study will start in July 2015 and will run for 3 years. Thereafter the follow-up will be completed in 6 months, followed by 6 months for data collecting, analysing and reporting. The total duration of the study is 4 years.

Who is funding the study?

Fonds NutsOhra and the Amsterdam UMC, location Academic Medical Center Amsterdam.

Who is the main contact?

1. Dr Lotte Boxhoorn
L.boxhoorn@amsterdamumc.nl
2. Dr Marc Besselink
m.g.besselink@amsterdamumc.nl

Contact information

Type(s)

Scientific

Contact name

Prof Marc Besselink

Contact details

Amsterdam UMC, location VUMC
Department of Surgery
De Boelelaan 1117
Amsterdam
Netherlands
1081 HV
+31-20-4444400
m.g.besselink@amsterdamumc.nl

Type(s)

Scientific

Contact name

Dr Lotte Boxhoorn

Contact details

St. Antonius Hospital
Dutch Pancreatitis Study Group
Nieuwegein

Netherlands
PO Box 2500 / 3430 EM
+31 (0)88 3207053
L.boxhoorn@amsterdamumc.nl

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

N/A

Study information

Scientific Title

Postponed or immediate drainage of infected necrotizing pancreatitis: a pragmatic parallel group randomized controlled multicenter superiority trial

Acronym

POINTER trial

Study objectives

Immediate catheter drainage is clinically and economically superior to postponed catheter drainage within the step-up approach in infected necrotizing pancreatitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The medical ethics committee of the Amsterdam UMC, location Academic Medical Center Amsterdam, 19/06/2015, NL52361.018.15

Study design

Pragmatic parallel-group randomized controlled multicenter superiority trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Infected necrotizing pancreatitis

Interventions

Immediate catheter drainage after diagnosing infected necrosis while starting antibiotic treatment versus current standard treatment with postponing catheter drainage under antibiotic treatment (preferably until walled-off necrosis). If necessary a necrosectomy will be performed and postponed, if feasible, until the stage of walled-off necrosis in both treatment arms.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Current primary outcome measure as of 12/04/2021:

Comprehensive Complication Index (CCI), including all complications other than pre-existent complications (e.g. treatment for infected (extra) pancreatic necrosis) occurring after randomization until 6 months after randomization, and graded according to the Clavien-Dindo classification.

Previous primary outcome measure:

The Comprehensive Complication Index (CCI), including all complications between randomization and 6 months after

Key secondary outcome(s)

Current secondary outcome measures as of 12/04/2021:

1. Mortality
2. New onset (multi-)organ failure
3. Bleeding requiring intervention
4. Perforation of a visceral organ requiring intervention
5. Enterocutaneous fistula
6. Pancreaticocutaneous fistula
7. Incisional hernia
8. Wound infections
9. Endocrine and exocrine pancreas insufficiency
10. Number of patients with severe complications (Clavien-Dindo III or higher)
11. Number of patients per Clavien-Dindo classification
12. Number of surgical, endoscopic and radiologic interventions
13. Length of hospital stay
14. Length of ICU admission
15. QALYs
16. Total direct and indirect costs
17. Budget impact

All secondary endpoints occurring within 6 months after randomization will be measured

Previous secondary outcome measures:

1. Mortality
2. New onset (multi-)organ failure
3. Bleeding requiring intervention
4. Perforation requiring intervention
5. Fistula
6. Incisional hernia
7. Wound infections
8. Endocrine and exocrine pancreas insufficiency

9. Number of patients with severe complications (Clavien-Dindo III or higher)

10. Number of patients per Clavien-Dindo classification

11. Number of (re-)interventions

12. Hospital and ICU length of stay

13. QALYs

14. (In)direct costs

15. Budget impact

All secondary endpoints occurring within 6 months after randomization will be measured.

Completion date

11/04/2019

Eligibility

Key inclusion criteria

Adult patients with (suspected) infected necrotizing pancreatitis; all patients with necrotizing pancreatitis will be screened for eligibility including a protocolized approach to patients with signs of infection

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

104

Key exclusion criteria

1. More than 35 days after onset of acute pancreatitis

2. Indication for emergency laparotomy for abdominal catastrophe (e.g. bleeding, bowel perforation, abdominal compartment syndrome)

3. Previous retroperitoneal intervention for necrotizing pancreatitis

4. Documented chronic pancreatitis

Date of first enrolment

04/08/2015

Date of final enrolment

11/10/2019

Locations

Countries of recruitment

Netherlands

Study participating centre

Amsterdam UMC, location Academic Medical Center

Amsterdam

Netherlands

-

Study participating centre

Erasmus Medical Center

Rotterdam

Netherlands

-

Study participating centre

St. Antonius Hospital

Nieuwegein

Netherlands

-

Study participating centre

Maastricht University Medical Center

Maastricht

Netherlands

-

Study participating centre

Radboudumc

Nijmegen

Netherlands

-

Study participating centre

University Medical Center Groningen

Groningen

Netherlands

-

Study participating centre
University Medical Center Utrecht
Utrecht
Netherlands

-

Study participating centre
Jeroen Bosch Hospital
's-Hertogenbosch
Netherlands

-

Study participating centre
Reinier de Graaf Gasthuis
Delft
Netherlands

-

Study participating centre
Amsterdam UMC, location VU University Medical Center
Amsterdam
Netherlands

-

Study participating centre
Meander Medical Center
Amersfoort
Netherlands

-

Study participating centre
Hospital Gelderse Vallei
Ede
Netherlands

-

Study participating centre

Maxima Medisch Centrum
Veldhoven
Netherlands
-

Study participating centre
Isala Klinieken
Zwolle
Netherlands
-

Study participating centre
Rijnstate Hospital
Arnhem
Netherlands
-

Study participating centre
Medisch Spectrum Twente
Enschede
Netherlands
-

Study participating centre
Catharina Hospital
Eindhoven
Netherlands
-

Study participating centre
Gelre Hospital
Apeldoorn
Netherlands
-

Study participating centre

Medical Center Leeuwarden

Leeuwarden
Netherlands

-

**Study participating centre
Onze Lieve Vrouwe Gasthuis**

Amsterdam
Netherlands

-

**Study participating centre
Amphia Hospital**

Breda
Netherlands

-

**Study participating centre
Maastad Hospital**

Rotterdam
Netherlands

-

**Study participating centre
Spaarne Gasthuis**

Haarlem
Netherlands

-

**Study participating centre
Albert Schweitzer Hospital**

Dordrecht
Netherlands

-

Sponsor information

Organisation

Academic Medical Center

ROR

<https://ror.org/03t4gr691>

Funder(s)

Funder type

Charity

Funder Name

Fonds NutsOhra

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. dr. Marc Besselink (m.g.besselink@amsterdamumc.nl)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		07/10/2021	07/10/2021	Yes	No
Results article		17/07/2023	17/07/2023	Yes	No
Protocol article	protocol	25/04/2019	29/04/2019	Yes	No
Other publications	Secondary analysis	25/04/2025	02/09/2025	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes